Efficacy and safety of olodaterol once daily delivered via Respimat® in patients with GOLD 2-4 COPD: results from two replicate 48-week studies

Gary T Ferguson, Gregory J Feldman, Peter Hofbauer, Alan Hamilton, Lisa Allen, Lawrence Korducki, Paul Sachs, Gary T Ferguson, Gregory J Feldman, Peter Hofbauer, Alan Hamilton, Lisa Allen, Lawrence Korducki, Paul Sachs

Abstract

Background: Olodaterol is a long-acting β2-agonist with a 24-hour bronchodilator profile. Two replicate, randomized, double-blind, placebo-controlled, parallel-group, Phase III trials were performed as part of a comprehensive clinical program to investigate the long-term safety and efficacy of olodaterol in patients with moderate to very severe chronic obstructive pulmonary disease (COPD) receiving usual-care background therapy.

Methods: Patients received olodaterol 5 μg or 10 μg or placebo once daily for 48 weeks. Coprimary end points were forced expiratory volume in 1 second (FEV1) area under the curve from 0 to 3 hours (AUC0-3) response (change from baseline), and trough FEV1 response at 12 weeks. Secondary end points included additional lung function assessments, use of rescue medications, FEV1 AUC response from 0 to 12 hours, and Patient Global Rating over 48 weeks.

Results: Overall, 624 and 642 patients were evaluated in studies 1222.11 and 1222.12, respectively. In both studies, olodaterol 5 μg and 10 μg significantly improved the FEV1 AUC0-3 response (P<0.0001) and trough FEV1 (study 1222.11, P<0.0001; study 1222.12, P<0.05, post hoc) at week 12, with an incidence of adverse events comparable with that of placebo. Secondary end points supported the efficacy of olodaterol.

Conclusion: These studies demonstrate the long-term efficacy and safety of once-daily olodaterol 5 μg and 10 μg in patients with moderate to very severe COPD continuing with usual-care maintenance therapy.

Trial registration: ClinicalTrials.gov NCT00782210 NCT00782509.

Keywords: bronchodilator; chronic obstructive pulmonary disease; olodaterol.

Figures

Figure 1
Figure 1
Trial design for studies 1222.11 and 1222.12. Abbreviation: QD, once daily.
Figure 2
Figure 2
Participant flow in study 1222.11 (A) and study 1222.12 (B). Notes:aOne patient not treated because electrocardiogram was reviewed after randomization and was abnormal; bone patient was excluded due to lack of Health Insurance Portability and Accountability Act authorization; one patient discontinued prior to first drug dose. Abbreviation: QD, once daily.
Figure 3
Figure 3
FEV1 AUC0–3 (A) and trough FEV1 (B) over 48 weeks in study 1222.11 and study 1222.12. Abbreviations: FEV1, forced expiratory volume in 1 second; AUC0–3, area under the curve from 0–3 hours.
Figure 4
Figure 4
FEV1 over time from 1 hour pre-dose to 3 hours post-dose in study 1222.11 and study 1222.12 at day 1 (A) and week 12 (B). Abbreviations: FEV1, forced expiratory volume in 1 second; h, hours.

References

    1. Tashkin DP, Ferguson GT. Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease. Respir Res. 2013;14:49.
    1. Global Initiative for Chronic Obstructive Lung Disease Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Updated 2013. [Accessed July 15, 2013]. Available from: .
    1. Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359(15):1543–1554.
    1. Dahl R, Greefhorst LAPM, Nowak D, et al. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;164(5):778–784.
    1. Cazzola M, Santangelo G, Piccolo A, et al. Effect of salmeterol and formoterol in patients with chronic obstructive pulmonary disease. Pulm Pharmacol. 1994;7(2):103–107.
    1. Cazzola M, Matera MG. Novel long-acting bronchodilators for COPD and asthma. Br J Pharmacol. 2008;155(3):291–299.
    1. Toy EL, Beaulieu NU, McHale JM, et al. Treatment of COPD: relationships between daily dosing frequency, adherence, resource use, and costs. Respir Med. 2011;105(3):435–441.
    1. Bouyssou T, Casarosa P, Naline E, et al. Pharmacological characterization of olodaterol, a novel inhaled β2-adrenoceptor agonist exerting a 24-hour-long duration of action in preclinical models. J Pharmacol Exp Ther. 2010;334(1):53–62.
    1. Casarosa P, Kollak I, Kiechle T, et al. Functional and biochemical rationales for the 24-hour-long duration of action of olodaterol. J Pharmacol Exp Ther. 2011;337(3):600–609.
    1. Bouyssou T, Hoenke C, Rudolf K, et al. Discovery of olodaterol, a novel inhaled β2-adrenoceptor agonist with a 24 h bronchodilatory efficacy. Bioorg Med Chem Lett. 2010;20(4):1410–1414.
    1. O’Byrne PM, van der Linde J, Cockcroft DW, et al. Prolonged bronchoprotection against inhaled methacholine by inhaled BI 1744, a long-acting β2-agonist, in patients with mild asthma. J Allergy Clin Immunol. 2009;124(6):1217–1221.
    1. O’Byrne PM, D’Urzo T, Gahlemann M, Hart L, Wang F, Beck E. Dose-finding study of once-daily treatment with olodaterol, a novel long-acting β2-agonist, in patients with asthma. Am J Respir Crit Care Med. 2012;185:A3963. (Abstract)
    1. van Noord JA, Smeets JJ, Drenth BM, et al. 24-hour bronchodilation following a single dose of the novel β2-agonist olodaterol in COPD. Pulm Pharmacol Ther. 2011;24(6):666–672.
    1. Joos G, Aumann JL, Coeck C, Korducki L, Hamilton AL, van Noord J. Comparison of 24-hour FEV1 profile for once-daily versus twice-daily treatment with olodaterol, a novel long-acting β2-agonist, in patients with COPD. Am J Respir Crit Care Med. 2012;185:A2930. (Abstract)
    1. van Noord JA, Korducki L, Hamilton A, Koker P. Four weeks once daily treatment with BI 1744 CL, a novel long-acting β2-agonist, is effective in COPD patients. Am J Respir Crit Care Med. 2009;179:A6183. (Abstract)
    1. US Department of Health and Human Services, US Food and Drug Administration, Center for Drug Evaluation and Research (CDER) Guidance for industry. Chronic obstructive pulmonary disease: developing drugs for treatment. Draft guidance. [Accessed April 26, 2012]. Available from: .
    1. Redelmeier DA, Guyatt GH, Goldstein RS. Assessing the minimal important difference in symptoms: a comparison of two techniques. J Clin Epidemiol. 1996;49(11):1215–1219.
    1. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J. 2005;26(2):319–338.
    1. European Medicines Agency Statistical principles for clinical trials. [Accessed July 24, 2013]. Available from: .
    1. McGarvey L, Koch A, Sachs P, et al. 48-week administration of olodaterol QD via Respimat® vs placebo and formoterol BID in patients with COPD: Pooled safety analysis. Eur Respir J. 2013;42(Suppl 57):749s–P3633. (Abstract)
    1. Tomlinson B, Cruickshank JM, Hayes Y, et al. Selective β-adrenoceptor partial agonist effects of pindolol and xamoterol on skeletal muscle assessed by plasma creatine kinase changes in healthy subjects. Br J Clin Pharmacol. 1990;30(5):665–672.
    1. Albert P, Agusti A, Edwards L, et al. Bronchodilator responsiveness as a phenotypic characteristic of established chronic obstructive pulmonary disease. Thorax. 2012;67(8):701–708.
    1. Koch A, Paggiaro P, Hamilton A, et al. Symptomatic benefit of olodaterol QD delivered via Respimat® vs placebo and formoterol BID in patients with COPD: Combined analysis from two 48-week studies. Eur Respir J. 2013;42(Suppl 57):145s–P763. (Abstract)
    1. Koch A, Pizzichini E, Hamilton A, et al. Lung function efficacy of olodaterol QD delivered via Respimat® vs placebo and formoterol BID in patients with COPD: two 48-week studies. Eur Respir J. 2013;42(Suppl 57):146s–P764. (Abstract)
    1. Ferguson GT, Sachs P, Hamilton A, Tetzlaff K, Korducki L, Koch A. Efficacy of olodaterol once daily (QD) via Respimat® in GOLD 2/3 COPD patients not receiving background therapy: pooled data from 48-week studies; Abstract 727A presented at CHEST; Chicago, IL, USA. October 26–31, 2013.
    1. European Medicines Agency Guideline on clinical investigation of medicinal products in the treatment of chronic obstructive pulmonary disease (COPD) [Accessed August 7, 2013]. Available from: .
    1. Derom E, Westerman J, Grönke L, et al. The 24-hour lung function profile of once-daily tiotropium and olodaterol fixed-dose combination compared with placebo and monotherapies in chronic obstructive pulmonary disease (VIVACITO); Abstract D44 presented at American Thoracic Society; San Diego, CA, USA. May 16–21, 2014.
    1. Lange P, Aumann J-L, Derom E, et al. The 24-h FEV1 time profile of olodaterol QD delivered via Respimat® in COPD: results from two 6-week studies. Eur Respir J. 2013;42(Suppl 57):982s–4635. (Abstract)
    1. Feldman G, Bernstein J, Hamilton A, Nivens C, Wang F, LaForce C. The 24-hour FEV1time profile of olodaterol once daily (QD) via Respimat® and formoterol twice daily (BID) via Aerolizer® in patients with COPD: results from two 6-week studies; Abstract 749A presented at CHEST; Chicago, IL, USA. October 26–31, 2013.
    1. Maltais F, Kirsten A, Hamilton A, De Sousa D, Wang F, Decramer M. Evaluation of the effects of olodaterol on exercise endurance in patients with COPD: results from two 6-week studies; Abstract 748A presented at CHEST; Chicago, IL, USA. October 26–31, 2013.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner